9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Alexion Pharmaceuticals, Inc.
352 Knotter Drive, P.O. Box 868
Cheshire, CT 06410

Phone: 203-271-8296
Fax: 203-271-8192
Website: http://www.alexionpharm.com

Public Relations

General Information
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of therapeutic products to treat patients with a wide array of severe disease states, including hematologic, cardiovascular and autoimmune disorders. The company's pipeline of antibody therapeutics is specifically focused on providing important treatment advances in areas of severe unmet medical need. Alexion is in the last phase of clinical development for its two lead product candidates and is initiating preparations for commercialization. The first lead product candidate, eculizumab, targets the treatment of a rare and severe hematologic disorder known as PNH. The second product candidate, pexelizumab, which is being developed in collaboration with Procter & Gamble Pharmaceuticals, is aimed at treating patients undergoing open heart surgery as well as patients suffering from an acute heart attack. The company was founded in New Haven, Connecticut in 1992.

Research Activities
C5 inhibitors, rare blood disorders, cardiovascular disease, and autoimmune disease.

Other Information
Ownership: Public
Stock Symbol: ALXN
CT Employees: 175
World Employees: 200